Amazon Prime Air Cargo Plane Crash Kills Five at Miami Airport 
Ingenia Rejects A$1.9 Billion Warburg Pincus Takeover Bid 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Brazil Court Suspends Sigma Lithium Mine Operations 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
Huawei Launches Mate XT2 Foldable Phone in China 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Trump Signs Order to Cut Routine Childhood Vaccines 
Add as a preferred source on Google
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
